Literature DB >> 18556669

Modeling immune system control of atherogenesis.

Francesco Pappalardo1, Salvatore Musumeci, Santo Motta.   

Abstract

MOTIVATION: Atherosclerosis is a disease that is present in almost all humans, typically beginning in early adolescence. It is a human disease broadly investigated, that is amenable to quantitative analysis. Oxidized low-density lipoproteins (LDLs) and their autoantibodies are involved in the development of atherosclerosis in animal models, but their role in humans is still not clear. Computer models may represent a virtual environment to perform experiments not possible in human volunteers that can provide a useful instrument for monitoring both the evolution of atherosclerotic lesions and to quantify the efficacy of treatments, including vaccines, oriented to reduce the LDLs and their oxidized fraction.
RESULTS: We report the application of an agent-based model to model both the immune response to atherogenesis and the atheromatous plaque progression in a generic artery wall. The level of oxidized LDLs, the immune humoral response with production of autoantibodies, the macrophages activity and the formation of foam cells are in good agreement with available clinical data, including the formation of atheromatous plaques in patients affected by hypercholesterolemia. AVAILABILITY: The model is available at http://www.immunogrid.eu/atherogenesis/

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556669     DOI: 10.1093/bioinformatics/btn306

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  10 in total

Review 1.  Systems immunology: a survey of modeling formalisms, applications and simulation tools.

Authors:  Vipin Narang; James Decraene; Shek-Yoon Wong; Bindu S Aiswarya; Andrew R Wasem; Shiang Rong Leong; Alexandre Gouaillard
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Bifurcation and dynamics in a mathematical model of early atherosclerosis: How acute inflammation drives lesion development.

Authors:  Alexander D Chalmers; Anna Cohen; Christina A Bursill; Mary R Myerscough
Journal:  J Math Biol       Date:  2015-03-03       Impact factor: 2.259

3.  Towards a comprehensive assessment of QSP models: what would it take?

Authors:  Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-13       Impact factor: 2.410

4.  SimB16: modeling induced immune system response against B16-melanoma.

Authors:  Francesco Pappalardo; Ivan Martinez Forero; Marzio Pennisi; Asis Palazon; Ignacio Melero; Santo Motta
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

Review 5.  Immunoinformatics: current trends and future directions.

Authors:  Joo Chuan Tong; Ee Chee Ren
Journal:  Drug Discov Today       Date:  2009-04-18       Impact factor: 7.851

6.  In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform.

Authors:  Giulia Russo; Marzio Pennisi; Epifanio Fichera; Santo Motta; Giuseppina Raciti; Marco Viceconti; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2020-12-14       Impact factor: 3.169

7.  A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY.

Authors:  Francesco Pappalardo; Marie-Paule Lefranc; Pier-Luigi Lollini; Santo Motta
Journal:  Immunome Res       Date:  2010-02-18

8.  Systems approaches to computational modeling of the oral microbiome.

Authors:  Dimiter V Dimitrov; Julia Hoeng
Journal:  Front Physiol       Date:  2013-07-10       Impact factor: 4.566

Review 9.  In silico modeling of the immune system: cellular and molecular scale approaches.

Authors:  Mariagrazia Belfiore; Marzio Pennisi; Giuseppina Aricò; Simone Ronsisvalle; Francesco Pappalardo
Journal:  Biomed Res Int       Date:  2014-04-06       Impact factor: 3.411

10.  An agent-based model of leukocyte transendothelial migration during atherogenesis.

Authors:  Rita Bhui; Heather N Hayenga
Journal:  PLoS Comput Biol       Date:  2017-05-25       Impact factor: 4.779

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.